This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
February 18, 2025 - February 20, 2025
Progress is on the horizon for the GBM field as innovative therapies and a deeper understanding of glioblastoma biology begin to emerge. Servier’s recent approval of vorasidenib for Grade 2 IDH-mutant glioma has sparked renewed hope in a space that has long struggled with limited treatment options. This milestone brings inspiration to the glioblastoma community, where the urgent need for effective treatments remains.
As we look toward 2025, a year that could mark a turning point in glioblastoma treatment, it is more important than ever to unite the community and deepen our understanding of these critical developments. Securing new treatment approvals for patients who desperately need them is a mission that cannot wait.